By the same authors

From the same journal

Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis

Research output: Contribution to journalReview articlepeer-review

Standard

Allergen immunotherapy for insect venom allergy : a systematic review and meta-analysis. / Dhami, S.; Zaman, H.; Varga, E. M.; Sturm, G. J.; Muraro, A.; Akdis, C. A.; Antolín-Amérigo, D.; Bilò, M. B.; Bokanovic, D.; Calderon, M. A.; Cichocka-Jarosz, E.; Oude Elberink, J. N G; Gawlik, R.; Jakob, T.; Kosnik, M.; Lange, J.; Mingomataj, E.; Mitsias, D. I.; Mosbech, H.; Ollert, M.; Pfaar, O.; Pitsios, C.; Pravettoni, V.; Roberts, G.; Ruëff, F.; Sin, B. A.; Asaria, M.; Netuveli, G.; Sheikh, A.

In: ALLERGY, Vol. 72, No. 3, 01.03.2017, p. 342-365.

Research output: Contribution to journalReview articlepeer-review

Harvard

Dhami, S, Zaman, H, Varga, EM, Sturm, GJ, Muraro, A, Akdis, CA, Antolín-Amérigo, D, Bilò, MB, Bokanovic, D, Calderon, MA, Cichocka-Jarosz, E, Oude Elberink, JNG, Gawlik, R, Jakob, T, Kosnik, M, Lange, J, Mingomataj, E, Mitsias, DI, Mosbech, H, Ollert, M, Pfaar, O, Pitsios, C, Pravettoni, V, Roberts, G, Ruëff, F, Sin, BA, Asaria, M, Netuveli, G & Sheikh, A 2017, 'Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis', ALLERGY, vol. 72, no. 3, pp. 342-365. https://doi.org/10.1111/all.13077

APA

Dhami, S., Zaman, H., Varga, E. M., Sturm, G. J., Muraro, A., Akdis, C. A., Antolín-Amérigo, D., Bilò, M. B., Bokanovic, D., Calderon, M. A., Cichocka-Jarosz, E., Oude Elberink, J. N. G., Gawlik, R., Jakob, T., Kosnik, M., Lange, J., Mingomataj, E., Mitsias, D. I., Mosbech, H., ... Sheikh, A. (2017). Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. ALLERGY, 72(3), 342-365. https://doi.org/10.1111/all.13077

Vancouver

Dhami S, Zaman H, Varga EM, Sturm GJ, Muraro A, Akdis CA et al. Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. ALLERGY. 2017 Mar 1;72(3):342-365. https://doi.org/10.1111/all.13077

Author

Dhami, S. ; Zaman, H. ; Varga, E. M. ; Sturm, G. J. ; Muraro, A. ; Akdis, C. A. ; Antolín-Amérigo, D. ; Bilò, M. B. ; Bokanovic, D. ; Calderon, M. A. ; Cichocka-Jarosz, E. ; Oude Elberink, J. N G ; Gawlik, R. ; Jakob, T. ; Kosnik, M. ; Lange, J. ; Mingomataj, E. ; Mitsias, D. I. ; Mosbech, H. ; Ollert, M. ; Pfaar, O. ; Pitsios, C. ; Pravettoni, V. ; Roberts, G. ; Ruëff, F. ; Sin, B. A. ; Asaria, M. ; Netuveli, G. ; Sheikh, A. / Allergen immunotherapy for insect venom allergy : a systematic review and meta-analysis. In: ALLERGY. 2017 ; Vol. 72, No. 3. pp. 342-365.

Bibtex - Download

@article{21d513b7054c42818b685c0614ae1b93,
title = "Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis",
abstract = "Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines on Allergen Immunotherapy (AIT) for the management of insect venom allergy. To inform this process, we sought to assess the effectiveness, cost-effectiveness and safety of AIT in the management of insect venom allergy. Methods: We undertook a systematic review, which involved searching 15 international biomedical databases for published and unpublished evidence. Studies were independently screened and critically appraised using established instruments. Data were descriptively summarized and, where possible, meta-analysed. Results: Our searches identified a total of 16 950 potentially eligible studies; of which, 17 satisfied our inclusion criteria. The available evidence was limited both in volume and in quality, but suggested that venom immunotherapy (VIT) could substantially reduce the risk of subsequent severe systemic sting reactions (OR = 0.08, 95% CI 0.03–0.26); meta-analysis showed that it also improved disease-specific quality of life (risk difference = 1.41, 95% CI 1.04–1.79). Adverse effects were experienced in both the build-up and maintenance phases, but most were mild with no fatalities being reported. The very limited evidence found on modelling cost-effectiveness suggested that VIT was likely to be cost-effective in those at high risk of repeated systemic sting reactions and/or impaired quality of life. Conclusions: The limited available evidence suggested that VIT is effective in reducing severe subsequent systemic sting reactions and in improving disease-specific quality of life. VIT proved to be safe and no fatalities were recorded in the studies included in this review. The cost-effectiveness of VIT needs to be established.",
keywords = "Allergy, anaphylaxis, hymenoptera venom allergy, insect venom allergy, systemic sting reaction",
author = "S. Dhami and H. Zaman and Varga, {E. M.} and Sturm, {G. J.} and A. Muraro and Akdis, {C. A.} and D. Antol{\'i}n-Am{\'e}rigo and Bil{\`o}, {M. B.} and D. Bokanovic and Calderon, {M. A.} and E. Cichocka-Jarosz and {Oude Elberink}, {J. N G} and R. Gawlik and T. Jakob and M. Kosnik and J. Lange and E. Mingomataj and Mitsias, {D. I.} and H. Mosbech and M. Ollert and O. Pfaar and C. Pitsios and V. Pravettoni and G. Roberts and F. Ru{\"e}ff and Sin, {B. A.} and M. Asaria and G. Netuveli and A. Sheikh",
note = "{\textcopyright} 2016 The Authors",
year = "2017",
month = mar,
day = "1",
doi = "10.1111/all.13077",
language = "English",
volume = "72",
pages = "342--365",
journal = "ALLERGY",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Allergen immunotherapy for insect venom allergy

T2 - a systematic review and meta-analysis

AU - Dhami, S.

AU - Zaman, H.

AU - Varga, E. M.

AU - Sturm, G. J.

AU - Muraro, A.

AU - Akdis, C. A.

AU - Antolín-Amérigo, D.

AU - Bilò, M. B.

AU - Bokanovic, D.

AU - Calderon, M. A.

AU - Cichocka-Jarosz, E.

AU - Oude Elberink, J. N G

AU - Gawlik, R.

AU - Jakob, T.

AU - Kosnik, M.

AU - Lange, J.

AU - Mingomataj, E.

AU - Mitsias, D. I.

AU - Mosbech, H.

AU - Ollert, M.

AU - Pfaar, O.

AU - Pitsios, C.

AU - Pravettoni, V.

AU - Roberts, G.

AU - Ruëff, F.

AU - Sin, B. A.

AU - Asaria, M.

AU - Netuveli, G.

AU - Sheikh, A.

N1 - © 2016 The Authors

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines on Allergen Immunotherapy (AIT) for the management of insect venom allergy. To inform this process, we sought to assess the effectiveness, cost-effectiveness and safety of AIT in the management of insect venom allergy. Methods: We undertook a systematic review, which involved searching 15 international biomedical databases for published and unpublished evidence. Studies were independently screened and critically appraised using established instruments. Data were descriptively summarized and, where possible, meta-analysed. Results: Our searches identified a total of 16 950 potentially eligible studies; of which, 17 satisfied our inclusion criteria. The available evidence was limited both in volume and in quality, but suggested that venom immunotherapy (VIT) could substantially reduce the risk of subsequent severe systemic sting reactions (OR = 0.08, 95% CI 0.03–0.26); meta-analysis showed that it also improved disease-specific quality of life (risk difference = 1.41, 95% CI 1.04–1.79). Adverse effects were experienced in both the build-up and maintenance phases, but most were mild with no fatalities being reported. The very limited evidence found on modelling cost-effectiveness suggested that VIT was likely to be cost-effective in those at high risk of repeated systemic sting reactions and/or impaired quality of life. Conclusions: The limited available evidence suggested that VIT is effective in reducing severe subsequent systemic sting reactions and in improving disease-specific quality of life. VIT proved to be safe and no fatalities were recorded in the studies included in this review. The cost-effectiveness of VIT needs to be established.

AB - Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines on Allergen Immunotherapy (AIT) for the management of insect venom allergy. To inform this process, we sought to assess the effectiveness, cost-effectiveness and safety of AIT in the management of insect venom allergy. Methods: We undertook a systematic review, which involved searching 15 international biomedical databases for published and unpublished evidence. Studies were independently screened and critically appraised using established instruments. Data were descriptively summarized and, where possible, meta-analysed. Results: Our searches identified a total of 16 950 potentially eligible studies; of which, 17 satisfied our inclusion criteria. The available evidence was limited both in volume and in quality, but suggested that venom immunotherapy (VIT) could substantially reduce the risk of subsequent severe systemic sting reactions (OR = 0.08, 95% CI 0.03–0.26); meta-analysis showed that it also improved disease-specific quality of life (risk difference = 1.41, 95% CI 1.04–1.79). Adverse effects were experienced in both the build-up and maintenance phases, but most were mild with no fatalities being reported. The very limited evidence found on modelling cost-effectiveness suggested that VIT was likely to be cost-effective in those at high risk of repeated systemic sting reactions and/or impaired quality of life. Conclusions: The limited available evidence suggested that VIT is effective in reducing severe subsequent systemic sting reactions and in improving disease-specific quality of life. VIT proved to be safe and no fatalities were recorded in the studies included in this review. The cost-effectiveness of VIT needs to be established.

KW - Allergy

KW - anaphylaxis

KW - hymenoptera venom allergy

KW - insect venom allergy

KW - systemic sting reaction

UR - http://www.scopus.com/inward/record.url?scp=85012979805&partnerID=8YFLogxK

U2 - 10.1111/all.13077

DO - 10.1111/all.13077

M3 - Review article

AN - SCOPUS:85012979805

VL - 72

SP - 342

EP - 365

JO - ALLERGY

JF - ALLERGY

SN - 0105-4538

IS - 3

ER -